1. Home
  2. NMAI vs EOLS Comparison

NMAI vs EOLS Comparison

Compare NMAI & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NMAI

Nuveen Multi-Asset Income Fund of Beneficial Interest

HOLD

Current Price

$14.13

Market Cap

458.6M

Sector

Finance

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$5.95

Market Cap

384.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMAI
EOLS
Founded
2021
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
458.6M
384.6M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NMAI
EOLS
Price
$14.13
$5.95
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$15.50
AVG Volume (30 Days)
85.7K
718.6K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
13.14%
N/A
EPS Growth
N/A
1.23
EPS
0.64
N/A
Revenue
N/A
$297,176,000.00
Revenue This Year
N/A
$13.27
Revenue Next Year
N/A
$17.62
P/E Ratio
$21.86
N/A
Revenue Growth
N/A
11.61
52 Week Low
$11.99
$3.86
52 Week High
$14.38
$9.15

Technical Indicators

Market Signals
Indicator
NMAI
EOLS
Relative Strength Index (RSI) 58.26 42.99
Support Level $13.60 $5.45
Resistance Level $14.30 $7.16
Average True Range (ATR) 0.23 0.29
MACD 0.01 -0.00
Stochastic Oscillator 82.64 50.76

Price Performance

Historical Comparison
NMAI
EOLS

About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Share on Social Networks: